UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
December 1, 2005
Date of Report (Date of earliest event reported)
ANTIGENICS INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| DELAWARE
|
|
000-29089
|
|
06-1562417 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 630 Fifth Avenue, Suite 2100 |
|
|
New York, NY 10111
(Address of principal executive offices)
|
|
10111
(Zip Code) |
212-994-8200
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 1.01 Entry into a Material Definitive Agreement
On December 1, 2005, the Board of Directors of Antigenics Inc. (the “Company”) ratified
the recommendation of the Compensation Committee and appointed Bruce Leicher, Vice-President
General Counsel. In connection with the appointment, Mr. Leicher entered into an Employment
Agreement with the company effective November 28, 2005. The full text of the agreement is
filed as an exhibit to this current report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
The following exhibit is filed herewith:
| |
10.1 |
|
Employment agreement dated November 28, 2005 between Antigenics Inc. and Bruce Leicher |